#CurisLifesciencesIPO #PharmaIPO #NSEEmerge #SMEIPO #Pharmaceuticals #IndianMarkets #IPO2025 #HealthcareInvesting #CapitalMarkets #ContractManufacturing #GujaratBusiness #StockMarketIndia
Chandigarh: Gujarat-based pharmaceutical company Curis Lifesciences is set to enter capital markets with its initial public offering (IPO) beginning November 7, 2025. The company plans to raise Rs 27.52 crore through a fresh issue of 21.5 lakh shares, priced between Rs 120 and Rs 128 per share. This issue is a 100% fresh issue, meaning no shares will be offered through an offer-for-sale by existing shareholders.
The IPO subscription will remain open until November 11, with share allotment expected on November 12, and shares to be listed on the NSE Emerge platform starting November 14.
Company Profile and Business Segments
Curis Lifesciences primarily operates as a contract manufacturer for merchant exporters and domestic pharmaceutical suppliers. These two segments accounted for over 94 percent of the company’s revenue for the fiscal year 2024-25. The company manufactures a variety of pharmaceutical products including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments.
The company serves an impressive client list including J B Chemicals and Pharmaceuticals, Makers Laboratories, Troikaa Pharmaceuticals, Arova Pharma, Angel Biogenics, and Centurion Healthcare.
Use of IPO Proceeds
The net proceeds from the IPO will be used for several key purposes:
-
Upgrading and improving existing manufacturing facilities to enhance production capacity.
-
Constructing additional storage facilities for better inventory management.
-
Facilitating registration of products in overseas markets to support export expansion.
-
Partially repaying outstanding loans to strengthen financial health.
-
Allocating funds for working capital and general corporate purposes.
Financial Performance Highlights
Curis Lifesciences has demonstrated consistent growth in recent years:
-
For the fiscal year ended March 2025, the company reported a profit of Rs 6.1 crore, up 25.3% from Rs 4.9 crore in the previous year.
-
Revenue for the same period increased by 38.2% to Rs 49.1 crore, compared to Rs 35.6 crore a year earlier.
-
In the four-month period ending July 2025, the company earned a profit of Rs 2.87 crore on revenues of Rs 19.5 crore.
The company maintains solid financial ratios with a return on equity of 55.25%, EBITDA margin of 19.4%, and a controlled debt-to-equity ratio of 0.96 as of the latest fiscal year.
Leadership and Management Team
Curis Lifesciences is led by Chairman and Managing Director Dharmesh Dasharathbhai Patel, supported by Whole-Time Directors Piyush Gordhanbhai Antala and Jaimik Mansukhlal Patel. The management team brings strong industry experience to the company, guiding it through growth and market expansion.
Important Dates and Additional Details
-
IPO opens for subscription: November 7, 2025
-
Subscription closes: November 11, 2025
-
Share allotment date: November 12, 2025
-
Listing on NSE Emerge: November 14, 2025
-
Minimum lot size: 1,000 shares
The company’s merchant banker for the IPO is Finaax Capital Advisors.
This IPO presents an opportunity for investors to participate in the growth of a promising contract manufacturing pharmaceutical company with a strong client base and clear plans for capacity expansion and financial strengthening.
#CurisLifesciencesIPO #PharmaIPO #NSEEmerge #SMEIPO #Pharmaceuticals #IndianMarkets #IPO2025 #HealthcareInvesting #CapitalMarkets #ContractManufacturing #GujaratBusiness #StockMarketIndia
